ENCOMPASS HEALTH CORP

Company Overview

Encompass Health is a national post-acute care provider operating 166 inpatient rehabilitation hospitals (11,094 licensed beds) across 38 states and Puerto Rico, delivering specialized rehab for stroke, brain injury, spinal cord injury and related conditions. The business is highly Medicare‑exposed (~65% fee‑for‑service plus ~17% Medicare Advantage), grew 2024 net operating revenues to $5.37B with Adjusted EBITDA of ~$1.10B, and emphasizes measurable clinical outcomes (discharge‑to‑community rates, length‑of‑stay) and stroke certifications to support reimbursement and partnerships. Growth is driven by de novo hospitals, JV relationships with acute systems (~one‑third of hospitals), and outpatient/satellite expansions, while material regulatory and audit risks (CMS IRF rules, RAC/UPIC, FCA, Anti‑Kickback/Stark, state CON regimes) heavily influence operations. The company also runs centralized EMR/analytics and capital‑intensive expansion programs (substantial capex and development WIP) that shape cash flow and capital allocation choices.

Executive Compensation Practices

Compensation is likely weighted toward performance‑based pay that ties annual and long‑term incentives to financial and operational KPIs that matter to Encompass: same‑store discharge growth, net patient revenue per discharge, occupancy, Adjusted EBITDA and free cash flow, plus quality metrics (discharge‑to‑community, stroke certification rates and readmission/acceptance outcomes). Given material capex, debt covenants and stated dividend/buyback programs, long‑term awards likely include equity (RSUs/PSUs) designed to align executives with TSR, capital discipline and covenant compliance; the 10‑Q note about mark‑to‑market on deferred compensation also indicates nontrivial deferred/long‑term pay components. Labor and retention pressures (nurse/therapist turnover, rising salaries and benefits) mean short‑term incentives may incorporate workforce and productivity measures, and compliance/audit outcomes may factor into bonus adjustments to mitigate regulatory risk. Expect a mix of cash bonuses, equity incentives and deferred compensation with clawback and compliance provisions given exposure to CMS audits, billing appeals and potential FCA liability.

Insider Trading Considerations

Insider trading activity will often cluster around discrete, material events that change the reimbursement or audit outlook—quarterly results, CMS IRF‑PPS final rules, major RCD/audit developments or settlement announcements—and around capital events (de novo openings, large capex milestones, buyback authorizations, dividend changes). Because the company publicly signals buybacks and dividend policy and is covenant‑sensitive, insiders may be active near announced repurchase windows or after covenant relief events; however, blackout periods around earnings and deal‑related confidential information are likely enforced. Regulatory and enforcement risk (RAC/UPIC audits, appeals, FCA exposure, Anti‑Kickback/Stark issues) creates situations where insiders possess highly material non‑public information, increasing reliance on formal trading plans (e.g., Rule 10b5‑1) and strict compliance/insider‑trading policies. Traders watching insider filings should pay attention to timing relative to CMS publications, audit outcomes, capex disclosures and major JV transactions, and to equity awards/exercise activity disclosed in proxy/insider filings that may precede open‑market sales.